Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.72 -1.84%

-$0.18 today

Market cap
$1.27B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.34M

Average 4.58M

Returns on capital

Novavax, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-344.7%

avg 513.6%

ROIC

78.0%

avg -155.8%

ROA

37.4%

avg -42.2%

Analysis

ROIC is currently the strongest return metric at 78.0% versus its period average of -155.8%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

John Charles Jacobs

President, Chief Executive Officer & DirectorUSD 1.55M59——

Mark Casey

Executive Vice President, Chief Legal Officer & Corporate SecretaryUSD 984.26K63——

Elaine O'Hara

Executive Vice President & Chief Strategy OfficerUSD 947.01K58112.67K0.07%

James Patrick Kelly

Executive Vice President, Chief Financial Officer & TreasurerUSD 884.28K600<0.01%

Ian J. Watkins

Executive Vice President & Chief Human Resources Officer—63——

Richard Crowley

Executive Vice President & Chief Operating Officer—69——

Troy Morgan

Senior Vice President, Deputy General Counsel & Chief Compliance Officer—55——

Erika S. Trahan

Associate Director of Investor & Public Relations————

Naina Zaman

Director of Investor Relations————

Silvia Taylor

Executive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 7, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
-15.2% (5yr)2 analysts
RevenueN/AN/A-11.1%
-16.9% (5yr)3 analysts
Net IncomeN/AN/AN/A
-15.2% (5yr)3 analysts
EBITN/AN/AN/A
-14.1% (5yr)3 analysts

Analysis

Recent growth has been strongest in Revenue at -11.1% over three years. Forward estimates point to EBIT at -14.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Novavax, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NVAX's management, answered from reported figures.

Who manages NVAX?

Novavax, Inc. (NVAX) lists 10 active executives. The top listed executive is Ian J. Watkins, Executive Vice President & Chief Human Resources Officer.

Are NVAX insiders buying or selling?

Recent insider activity shows net buying of $34.36M.